Drugs / CRLX301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02380677 | Apr 2015 → Oct 2017 | — | NewLink Genetics Corporation | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRLX301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02380677 ↗ |
| Modality | Other / unclassified | “CRLX301, a nanoparticle drug conjugate containing docetaxel.” PMID 33594602 ↗ Feb 2021 |
| Route | Intravenous | “CRLX301 7.5 mg/m2 IV given every 3 weeks” NCT02380677 ↗ |